 Shares of Bausch Health Companies Inc. BHC, -6.53 dropped 7.8 in morning trading Friday, toward a 27-year low, after the drug and medical device maker confirmed a disappointing court decision regarding its patents protecting Xifaxan for treating irritable bowel syndrome. The stock had plunged 41.2 on Thursday after Bloomberg reported that some of the patents were ruled to be invalid. 